Tyra Biosciences (TYRA) Other Non-Current Liabilities (2020 - 2024)
Tyra Biosciences' (TYRA) quarterly Other Non-Current Liabilities came in at $3000.0 in Q4 2024, down 93.48% YoY from $46000.0 in Q1 2024, and down 72.73% on a QoQ basis from $11000.0 in Q3 2024.
Powered by 
Analysis
Tyra Biosciences (TYRA) Other Non-Current Liabilities (2020 - 2024) Analysis & Trends
Tyra Biosciences (TYRA) has 5 years of Other Non-Current Liabilities data on file, last reported at $3000.0 in Q4 2024.
- Quarterly Other Non-Current Liabilities fell 93.48% year-over-year to $3000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $3000.0 (down 93.48% YoY) and the FY2024 annual result came in at $3000.0, down 93.48% from the prior year.
- Other Non-Current Liabilities eased to $3000.0 in Q4 2024, from $11000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $434000.0 in Q3 2021 to a low of $3000.0 in Q4 2024.
- A 5-year average of $155533.3 and a median of $139000.0 in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Other Non-Current Liabilities jumped 162.14% — and 2024, when it tumbled 93.48%.
- Tracing TYRA's Other Non-Current Liabilities over 5 years: stood at $140000.0 in 2020, then jumped by 162.14% to $367000.0 in 2021, then slumped by 53.95% to $169000.0 in 2022, then plunged by 72.78% to $46000.0 in 2023, then plunged by 93.48% to $3000.0 in 2024.
- The last three Other Non-Current Liabilities figures came in at $3000.0 (Q4 2024), $11000.0 (Q3 2024), and $20000.0 (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | Tyra Biosciences | 1.94 Bn | 1.94 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | 11,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Mar 31, 2024 | 29,000.00 |
| Dec 31, 2023 | 46,000.00 |
| Sep 30, 2023 | 77,000.00 |
| Jun 30, 2023 | 108,000.00 |
| Mar 31, 2023 | 139,000.00 |
| Dec 31, 2022 | 169,000.00 |
| Sep 30, 2022 | 226,000.00 |
| Jun 30, 2022 | 261,000.00 |
| Mar 31, 2022 | 303,000.00 |
| Dec 31, 2021 | 367,000.00 |
| Sep 30, 2021 | 434,000.00 |
| Dec 31, 2020 | 140,000.00 |